These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 26315534)
1. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Corrales L; Gajewski TF Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534 [No Abstract] [Full Text] [Related]
2. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity. Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072 [TBL] [Abstract][Full Text] [Related]
3. Insight into the dichotomous regulation of STING activation in immunotherapy. Hu Z; Yang Y; Fang L; Zhou J; Zhang H Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600 [TBL] [Abstract][Full Text] [Related]
4. STING signaling: a key to therapeutic tumor immunity. Foote JB; Emens LA Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260 [No Abstract] [Full Text] [Related]
5. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Leventhal DS; Sokolovska A; Li N; Plescia C; Kolodziej SA; Gallant CW; Christmas R; Gao JR; James MJ; Abin-Fuentes A; Momin M; Bergeron C; Fisher A; Miller PF; West KA; Lora JM Nat Commun; 2020 Jun; 11(1):2739. PubMed ID: 32483165 [TBL] [Abstract][Full Text] [Related]
6. Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies. Huang M; Cha Z; Liu R; Lin M; Gafoor NA; Kong T; Ge F; Chen W Front Immunol; 2024; 15():1399926. PubMed ID: 38817608 [TBL] [Abstract][Full Text] [Related]
7. Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion. Wu J; Dobbs N; Yang K; Yan N Immunity; 2020 Jul; 53(1):115-126.e5. PubMed ID: 32640258 [TBL] [Abstract][Full Text] [Related]
9. Multi-Metallic Nanosheets Reshaping Immunosuppressive Tumor Microenvironment through Augmenting cGAS-STING Innate Activation and Adaptive Immune Responses for Cancer Immunotherapy. Peng Y; Liang S; Liu D; Ma K; Yun K; Zhou M; Hai L; Xu M; Chen Y; Wang Z Adv Sci (Weinh); 2024 Oct; 11(38):e2403347. PubMed ID: 39120546 [TBL] [Abstract][Full Text] [Related]
10. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Corrales L; Gajewski TF Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573 [TBL] [Abstract][Full Text] [Related]
12. The host STING pathway at the interface of cancer and immunity. Corrales L; McWhirter SM; Dubensky TW; Gajewski TF J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184 [TBL] [Abstract][Full Text] [Related]
13. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review. Ye Y; Xu C; Chen F; Liu Q; Cheng N Front Immunol; 2021; 12():771201. PubMed ID: 34899721 [TBL] [Abstract][Full Text] [Related]
14. Histamine in cancer immunology and immunotherapy. Current status and new perspectives. Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067 [TBL] [Abstract][Full Text] [Related]
15. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989 [TBL] [Abstract][Full Text] [Related]
16. Is cancer vaccination feasible at older age? Gravekamp C; Jahangir A Exp Gerontol; 2014 Jun; 54():138-44. PubMed ID: 24509231 [TBL] [Abstract][Full Text] [Related]
17. Basic concepts in glioma immunology. Parney IF Adv Exp Med Biol; 2012; 746():42-52. PubMed ID: 22639158 [TBL] [Abstract][Full Text] [Related]
18. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. Ginefra P; Lorusso G; Vannini N Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431 [TBL] [Abstract][Full Text] [Related]
19. The cGAS-STING Pathway: A Promising Immunotherapy Target. Ou L; Zhang A; Cheng Y; Chen Y Front Immunol; 2021; 12():795048. PubMed ID: 34956229 [TBL] [Abstract][Full Text] [Related]
20. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer. Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]